ADVAIR

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

, S S, I I, I I, .
Therapeutic delivery. 2019 May;10(5)273-280.
This Industry Update covers the period from 1 to 31 January 2019 and is based on information sourced from company press releases, scientific literature, patents and various news websites. Bristol-Myers Squibb (NY, USA) and Celgene (NJ, USA) announced a merger to create one of the largest oncology-fo
PMID 31094291

The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age.

Yoshihara S, Tsubaki T, Ikeda M, Lenney W, Tomiak R, Hattori T, Hashimoto K, Soutome T, Kato S.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2019 03;30(2)195-203.
Fluticasone propionate 50 μg/salmeterol xinafoate 25 μg (FP/SAL) is widely used in adults and children with asthma, but there is sparse information on its use in very young children. This was a randomized, double-blind, multicentre, controlled trial conducted in children aged 8 months to 4 yea
PMID 30556939

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.

Wedzicha JA, Singh D, Tsiligianni I, Jenkins C, Fucile S, Fogel R, Shen S, Goyal P, Mezzi K, Kostikas K.
Respiratory research. 2019 Jan;20(1)4.
The burden of chronic obstructive lung disease (COPD) is increasing in women, with recent evidence suggesting gender differences in disease characteristics and potentially in treatment outcomes. FLAME was a 52-week randomized controlled trial in patients with severe-to-very-severe COPD and a history
PMID 30621717

Advair : combination treatment with fluticasone propionate/salmeterol in the treatment of asthma